Craig Mello

Type: Person
Name: Craig Mello
First reported 10 hours ago - Updated 8 hours ago - 1 reports

Experimental Drug Jams Ebola Gene To Fight The Virus

A man stands above a new Ebola treatment center in Monrovia, Liberia. Health workers in Liberia, the hardest-hit nation, have turned people away from treatment units because of shortages of beds and staff. Pascal Guyot/AFP/ hide captioni toggle caption ... [Published NPR - 10 hours ago]
Entities: Michael Wong, RNA, Ebola, Drugs
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum

MARLBOROUGH, Mass., Sept. 29, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted ... [Published Scottrade - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

3 http://www.skipjack-nathan.org/saling.php 75391787

The recruiter sends the results of this screening to MEPS, in advance, to be reviewed by MEPS medical personnel. If the prescreening shows a medical condition which is obviously disqualifying, with no chance of a waiver (example, you are blind, or missing ... [Published Student Village - Sep 28 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference

MARLBOROUGH, Mass., Sept. 18, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted ... [Published 4 Traders - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

RXi Pharmaceuticals Strengthens Intellectual Property Portfolio

MARLBOROUGH, Mass., Sept. 17, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted ... [Published 4 Traders - Sep 17 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 2 reports

RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises

Related Stocks RXII - Rxi PharmaceuticalsSym Last Chg Pct Volume RXII2.44-1.11-31.27%5,783,200 MARLBOROUGH, Mass. , Sept. 11, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing ... [Published Barchart - Sep 11 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGOThe presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com.About RXI-109 Clinical TrialsRXi Pharmaceuticals' first clinical program ... [Published Industrial Info Financials - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

The Second Coming of RNAi

THE ART OF SILENCING: Small interfering RNA molecules are incorporated into an RNA-induced silencing complex where they bind and degrade target messenger RNAs (yellow with red rings). Taking advantage of this natural RNA interference (RNAi) pathway, researchers ... [Published The Scientist - Sep 02 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Running Interference

In Guinea, West Africa, February is the dry season; a dusty haze, stirred by the northeasterly harmattan winds, thickens the air. This year, the winds were harbingers of ill omen. That same month, Guineans began falling ill with symptoms ranging from ... [Published The Chemical Institute of Canada - Aug 26 2014]
First reported May 06 2014 - Updated May 06 2014 - 1 reports

CRISPR In the Courts

Here's an article from the Independent on the legal battles that are underway about CRISPR technology. On one level, it can be a somewhat ugly story, but it also shows how much of a discovery the technique has been, that people are willing to ... [Published In the Pipeline - May 06 2014]
First reported Apr 24 2014 - Updated Apr 24 2014 - 1 reports

CRISPR Therapeutics grabs $25 mln from Versant Ventures

CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9. PRESS RELEASE BASEL, Switzerland–(BUSINESS ... [Published PE Hub Blog - Apr 24 2014]

More Content

All (13) | News (11) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Experimental Drug Jams Ebola Gene To Fight The ... [Published NPR - 10 hours ago]
RXi Pharmaceuticals to Present at the 13th Annu... [Published Scottrade - Sep 29 2014]
3 http://www.skipjack-nathan.org/saling.php 753... [Published Student Village - Sep 28 2014]
RXi Pharmaceuticals to Present at the 7th Annua... [Published 4 Traders - Sep 18 2014]
RXi Pharmaceuticals Strengthens Intellectual Pr... [Published 4 Traders - Sep 17 2014]
RXi Pharmaceuticals Presented an Update on the ... [Published Barchart - Sep 11 2014]
RXi Pharmaceuticals Presented an Update on the ... [Published ADVFN UK - Sep 11 2014]
RXi Pharmaceuticals to Present at the Rodman & ... [Published PR Newswire - Sep 03 2014]
RXi Pharmaceuticals to Present at the Rodman & ... [Published Industrial Info Financials - Sep 03 2014]
The Second Coming of RNAi [Published The Scientist - Sep 02 2014]
Running Interference [Published The Chemical Institute of Canada - Aug 26 2014]
CRISPR In the Courts [Published In the Pipeline - May 06 2014]
CRISPR Therapeutics grabs $25 mln from Versant ... [Published PE Hub Blog - Apr 24 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CRISPR In the Courts [Published In the Pipeline - May 06 2014]
Here's an article from the Independent on the legal battles that are underway about CRISPR technology. On one level, it can be a somewhat ugly story, but it also shows how much of a discovery the technique has been, that people are willing to ...
CRISPR Therapeutics grabs $25 mln from Versant ... [Published PE Hub Blog - Apr 24 2014]
CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9. PRESS RELEASE BASEL, Switzerland–(BUSINESS ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.